DEN210033 is an FDA 510(k) submission (not cleared) for the Lenire Tinnitus Treatment Device. Classified as Combined Acoustic And Electrical External Stimulation Device For The Relief Of Tinnitus (product code QVN), Class II - Special Controls.
Submitted by Neuromod Devices Limited (Dublin 8, IE). The FDA issued a Not Cleared (DENG) decision on March 6, 2023 after a review of 565 days.
This device falls under the Ear, Nose, Throat FDA review panel, regulated under 21 CFR 874.3410 - the FDA ear, nose and throat device framework. The Traditional 510(k) pathway requires demonstration of substantial equivalence to a legally marketed predicate device - a standard the FDA determined was not met in this submission.
Device pattern: Regulatory edge-case submission. High predicate equivalence gap. With 565 days under review and no clearance granted, this submission reflects a case where the FDA could not confirm sufficient predicate equivalence - often indicating either a novel device category or unresolved safety and performance questions.
View all Neuromod Devices Limited devices